3 Biotechnology Stocks With Promising Pipelines
As the biotechnology sector continues to thrive amidst increasing drug discovery rates and a surge in research and development initiatives, now could be an ideal time for investors to consider positioning themselves in fundamentally strong biotech stocks. Many companies in the industry are expected to benefit from the Federal Reserve’s recent interest rate cuts, which have lowered borrowing costs and are anticipated to lead to increased investment and improved market sentiment. Advancements in technology are also accelerating the sector’s growth, with the global biotechnology market projected to reach $4.61 trillion by 2034, growing at a compound annual growth rate (CAGR) of 11.5%. Here, we will examine three notable biotech stocks: Amgen Inc. (AMGN), Regeneron Pharmaceuticals, Inc. (REGN), and Gilead Sciences, Inc. (GILD), which boast promising pipelines.
The Growing Biotech Landscape
The biotechnology industry is gaining momentum due to a rising tide of chronic diseases, the growing demand for personalized medicine, and the rapid evolution of drug discovery processes driven by cutting-edge technologies, including Artificial Intelligence (AI). In 2024, the U.S. Food and Drug Administration (FDA) has approved over 38 new drugs targeting critical health issues such as schizophrenia, urinary tract infections, breast cancer, lung cancer, and Alzheimer’s disease. The robust R&D landscape is expected to accelerate breakthroughs in the sector.
Stock #3: Amgen Inc. (AMGN)
Amgen Inc. is a global leader in discovering, developing, manufacturing, and delivering human therapeutics. The company’s product portfolio features major drugs such as Enbrel, Otezla, and Repatha. Recent developments include the FDA approval of Otezla for pediatric use, making it the first approved oral treatment for children aged 6-17 with moderate to severe plaque psoriasis. Additionally, AMGN’s BLINCYTO received authorization for treating patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.
In the third quarter ending September 30, 2024, Amgen reported total revenues of $8.50 billion, marking a 23.2% year-over-year increase. Their non-GAAP net income reached $3.02 billion, translating to an EPS of $5.58. Notably, AMGN’s shares surged 16.9% in the past six months and 25.2% over the last year, closing at $320.16. The company’s overall POWR Ratings indicate a solid performance, earning a “B” rating and ranking #25 out of 329 biotech stocks.
Stock #2: Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals is dedicated to discovering and commercializing medicines for diverse health conditions globally. Its key products include EYLEA, an injection for treating diabetic macular edema (DME), and Dupixent, approved as an add-on treatment for chronic obstructive pulmonary disease (COPD).
In the third quarter of 2024, Regeneron’s revenues increased to $3.72 billion, reflecting a 10.6% growth year-over-year. The company also reported non-GAAP EPS of $12.46. Currently, REGN shares have risen 7.5% over the past year, closing last session at $838.20. Its current POWR Ratings position REGN as a strong buy with an overall rating of “A” and ranking #9 in its industry.
Stock #1: Gilead Sciences, Inc. (GILD)
Gilead Sciences focuses on discovering, developing, and commercializing innovative medicines to meet unmet medical needs. The biopharmaceutical company’s portfolio includes several antiviral treatments, including Biktarvy and Descovy. Recently, Gilead expanded its partnership with AbTherx to enhance novel antibody discovery.
In the second quarter of 2024, Gilead’s revenues reached $6.95 billion, up 5.4% year-over-year. The company also surpassed consensus revenue estimates in all trailing four quarters. GILD’s stock has gained 36.2% in the past six months, closing at $88.82, and has an overall POWR Rating of “A,” indicating a strong buy with a robust outlook.
Conclusion
As the biotech industry prepares for significant growth driven by innovative drug discoveries and favorable economic conditions, investors might find opportunities in companies with promising pipelines like Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD). Each of these companies demonstrates solid fundamentals, making them potentially valuable additions to a diversified investment portfolio.